journal article·2026-03-26

Expanding global access to mRNA vaccines

Behnaz Eshaghi, Robert Langer, Ana Jaklenec

Nature Reviews Bioengineering· Volume 4· Issue 7
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Virus-based gene therapy research · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817–838 (2021).10.1038/s41573-021-00283-5 ↗
2. Leong, K. Y., Tham, S. K. & Poh, C. L. Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications. Virol. J. 22, 71 (2025).10.1186/s12985-025-02645-6 ↗
3. Fang, E. et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct. Target. Ther. 7, 94 (2022).10.1038/s41392-022-00950-y ↗
4. Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).10.1056/NEJMoa2035389 ↗
5. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).10.1056/NEJMoa2034577 ↗
6. Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).10.1038/nrd.2017.243 ↗
7. Sahin, U., Karikó, K. & Türeci, Ö. mRNA-based therapeutics — developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759–780 (2014).10.1038/nrd4278 ↗
8. Qin, S. et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct. Target. Ther. 7, 166 (2022).10.1038/s41392-022-01007-w ↗
9. Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R. & Anderson, D. G. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840–854 (2022).10.1038/s41587-022-01294-2 ↗
10. Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021).10.1038/s41578-021-00358-0 ↗
11. Li, S., Zheng, L., Zhong, J. & Gao, X. Advancing mRNA vaccines for infectious diseases: key components, innovations, and clinical progress. Essays Biochem. https://doi.org/10.1042/ebc20253009 (2025).10.1042/ebc20253009 ↗
12. Pardi, N. & Krammer, F. mRNA vaccines for infectious diseases — advances, challenges and opportunities. Nat. Rev. Drug Discov. 23, 838–861 (2024).10.1038/s41573-024-01042-y ↗
13. Liu, C. et al. mRNA-based cancer therapeutics. Nat. Rev. Cancer 23, 526–543 (2023).10.1038/s41568-023-00586-2 ↗
14. Sayour, E. J., Boczkowski, D., Mitchell, D. A. & Nair, S. K. Cancer mRNA vaccines: clinical advances and future opportunities. Nat. Rev. Clin. Oncol. 21, 489–500 (2024).10.1038/s41571-024-00902-1 ↗
15. Deyhimfar, R. et al. The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases. Heliyon 10, e26971 (2024).10.1016/j.heliyon.2024.e26971 ↗
16. Youssef, M., Hitti, C., Puppin Chaves Fulber, J. & Kamen, A. A. Enabling mRNA therapeutics: current landscape and challenges in manufacturing. Biomolecules 13, 1497 (2023).10.3390/biom13101497 ↗
17. Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M. & Marques, M. P. C. mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine 39, 2190–2200 (2021).10.1016/j.vaccine.2021.03.038 ↗
18. Wells, C. R. & Galvani, A. P. The global impact of disproportionate vaccination coverage on COVID-19 mortality. Lancet Infect. Dis. 22, 1254–1255 (2022).10.1016/S1473-3099(22)00417-0 ↗
19. Street, A., Kersaudy Kerhoas, M. & Ndlovu, Z. From equitable access to equitable innovation: rethinking bioengineering for global health. Nat. Rev. Bioeng. 2, 444–446 (2024).10.1038/s44222-024-00182-5 ↗
20. Dzau, V. et al. The 100 days mission: how a new medical-countermeasures network can deliver equity and innovation. Lancet 402, 1507–1510 (2023).10.1016/S0140-6736(23)01775-0 ↗
21. Zhang, G., Tang, T., Chen, Y., Huang, X. & Liang, T. mRNA vaccines in disease prevention and treatment. Signal Transduct. Target. Ther. 8, 365 (2023).10.1038/s41392-023-01579-1 ↗
22. May, M. After COVID-19 successes, researchers push to develop mRNA vaccines for other diseases. Nat. Med. 27, 930–932 (2021).10.1038/s41591-021-01393-8 ↗
23. Paczkowska, A. et al. The application of mRNA technology for vaccine production—current state of knowledge. Vaccines 13, 389 (2025).10.3390/vaccines13040389 ↗
24. Kaylor, A. Moderna’s COVID-19 vaccine mNEXSPIKE gains FDA approval. TechTarget https://www.techtarget.com/pharmalifesciences/news/366625275/Modernas-COVID-19-vaccine-mNEXSPIKE-gains-FDA-approval (2 June 2025).
25. Saraf, A. et al. An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial. Nat. Med. 30, 1363–1372 (2024).10.1038/s41591-024-02955-2 ↗
26. Dolgin, E. Self-copying RNA vaccine wins approval: what’s next? Nature 624, 14 (2023).10.1038/d41586-023-03859-w ↗
27. Silva-Pilipich, N., Beloki, U., Salaberry, L. & Smerdou, C. Self-amplifying RNA: a second revolution of mRNA vaccines against COVID-19. Vaccines 12, 318 (2024).10.3390/vaccines12030318 ↗
28. Wilson, E. et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N. Engl. J. Med. 389, 2233–2244 (2023).10.1056/NEJMoa2307079 ↗
29. Chuang, Y.-M. et al. A mosquito AgTRIO mRNA vaccine contributes to immunity against malaria. npj Vaccines 8, 88 (2023).10.1038/s41541-023-00679-x ↗
30. Matarazzo, L. & Bettencourt, P. J. G. mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV. Front. Immunol. 14, 1172691 (2023).10.3389/fimmu.2023.1172691 ↗
31. Vidal, S. J. et al. Mining the CD4 antigen repertoire for next-generation tuberculosis vaccines. Cell https://doi.org/10.1016/j.cell.2025.08.027 (2025). This article reports a systematic CD4+ T cell antigen screen that identifies a trivalent mRNA–LNP tuberculosis vaccine candidate with translational potential.10.1016/j.cell.2025.08.027 ↗
32. Rudman Spergel, A. K. et al. mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1/2 trial. Nat. Med. 31, 1484–1493 (2025).10.1038/s41591-025-03591-0 ↗
33. Zubair, A., Ahmad, H., Arif, M. M. & Ali, M. mRNA vaccines against HIV: hopes and challenges. HIV Med. 26, 824–838 (2025).10.1111/hiv.70024 ↗
34. Lusso, P. in Trends in mRNA Vaccine Research (eds Szabo, G. T. & Pardi, N.) 259–283 (Wiley, 2025).10.1002/9783527838394.ch9 ↗
35. Cevaal, P. M. et al. Efficient mRNA delivery to resting T cells to reverse HIV latency. Nat. Commun. 16, 4979 (2025).10.1038/s41467-025-60001-2 ↗
36. Morris, L. mRNA vaccines offer hope for HIV. Nat. Med. 27, 2082–2084 (2021).10.1038/s41591-021-01602-4 ↗
37. Willis, J. R. et al. Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans. Science 389, eadr8382 (2025).10.1126/science.adr8382 ↗
38. Parks, K. R. et al. Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial. Sci. Transl. Med. 17, eady6831 (2025).10.1126/scitranslmed.ady6831 ↗
39. Shim, I., Rogowski, L. & Venketaraman, V. Progress and recent developments in HIV vaccine research. Vaccines 13, 690 (2025).10.3390/vaccines13070690 ↗
40. Fan, T. et al. Therapeutic cancer vaccines: advancements, challenges and prospects. Signal Transduct. Target. Ther. 8, 450 (2023).10.1038/s41392-023-01674-3 ↗
41. Lorentzen, C. L., Haanen, J. B., Met, Ö. & Svane, I. M. Clinical advances and ongoing trials of mRNA vaccines for cancer treatment. Lancet Oncol. 23, e450–e458 (2022).10.1016/S1470-2045(22)00372-2 ↗
42. Goyal, F. et al. Advancing cancer immunotherapy: the potential of mRNA vaccines as a promising therapeutic approach. Adv. Ther. 7, 2300255 (2024).10.1002/adtp.202300255 ↗
43. Türeci, Ö. et al. Targeting the heterogeneity of cancer with individualized neoepitope vaccines. Clin. Cancer Res. 22, 1885–1896 (2016).10.1158/1078-0432.CCR-15-1509 ↗
44. Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632–644 (2024). This article reports results from a randomized phase IIb trial showing that an individualized neoantigen mRNA vaccine (mRNA-4157/V940) combined with pembrolizumab improves recurrence-free survival compared with pembrolizumab alone in patients with resected high-risk melanoma.10.1016/S0140-6736(23)02268-7 ↗
45. Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144–150 (2023).10.1038/s41586-023-06063-y ↗
46. Damle, S. R., Pillarisetty, V. G., Safyan, R. A. & Chiorean, E. G. A new dawn in cancer immunotherapy: the promise of mutant KRAS-specific vaccines. Transl. Gastroenterol. Hepatol. 10, 20 (2025).10.21037/tgh-24-121 ↗
47. Fu, Q. et al. mRNA vaccines in the context of cancer treatment: from concept to application. J. Transl. Med. 23, 12 (2025).10.1186/s12967-024-06033-6 ↗
48. Fu, R. et al. Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects. Signal Transduct. Target. Ther. 9, 118 (2024).10.1038/s41392-024-01824-1 ↗
49. Shariati, A. et al. mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy. Biomark. Res. 12, 157 (2024).10.1186/s40364-024-00692-9 ↗
50. Rohner, E., Yang, R., Foo, K. S., Goedel, A. & Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586–1600 (2022).10.1038/s41587-022-01491-z ↗
51. Koeberl, D. et al. Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia. Nature 628, 872–877 (2024).10.1038/s41586-024-07266-7 ↗
52. Attarwala, H., Lumley, M., Liang, M., Ivaturi, V. & Senn, J. Translational pharmacokinetic/pharmacodynamic model for mRNA-3927, an investigational therapeutic for the treatment of propionic acidemia. Nucleic Acid Ther. 33, 141–147 (2023).10.1089/nat.2022.0036 ↗
53. Baek, R. et al. Characterizing the mechanism of action for mRNA therapeutics for the treatment of propionic acidemia, methylmalonic acidemia, and phenylketonuria. Nat. Commun. 15, 3804 (2024).10.1038/s41467-024-47460-9 ↗
54. Geller, D. E., Crowley, C., Froehlich, J., Schwabe, C. & O’Carroll, M. WS10.03 Inhaled LUNAR®-CFTR mRNA (ARCT-032) is safe and well-tolerated: a phase 1 study. J. Cyst. Fibros. 23, S19 (2024).10.1016/S1569-1993(24)00166-8 ↗
55. Rowe, S. M. et al. Inhaled mRNA therapy for treatment of cystic fibrosis: interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study. J. Cyst. Fibros. 22, 656–664 (2023).10.1016/j.jcf.2023.04.008 ↗
56. Żak, M. M. & Zangi, L. Clinical development of therapeutic mRNA applications. Mol. Ther. 33, 2583–2609 (2025).10.1016/j.ymthe.2025.03.034 ↗
57. Zouali, M. Inverse vaccination for autoimmune diseases: insights into the role of B lymphocytes. Cells 14, 1085 (2025).10.3390/cells14141085 ↗
58. Zala, A. & Thomas, R. Antigen-specific immunotherapy to restore antigen-specific tolerance in type 1 diabetes and Graves’ disease. Clin. Exp. Immunol. 211, 164–175 (2023).10.1093/cei/uxac115 ↗
59. Chen, J. et al. LNP-mRNA vaccine prevents type 1 diabetes in non-obese diabetes mice. J. Control. Release 375, 513–523 (2024).10.1016/j.jconrel.2024.09.020 ↗
60. Krienke, C. et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science 371, 145–153 (2021).10.1126/science.aay3638 ↗
61. Liu, Y. et al. Generation of tolerogenic antigen-presenting cells in vivo via the delivery of mRNA encoding PDL1 within lipid nanoparticles. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-025-01373-0 (2025). This article reports the in vivo generation of tolerogenic antigen-presenting cells through LNP delivery of mRNA encoding PD-L1, suppressing T cell activation and preventing disease progression in mouse models of autoimmune disease.10.1038/s41551-025-01373-0 ↗
62. Liric Rajlic, I. et al. Translational kinetic-pharmacodynamics of mRNA-6231, an investigational mRNA therapeutic encoding mutein interleukin-2. CPT Pharmacomet. Syst. Pharmacol. 13, 1067–1078 (2024).10.1002/psp4.13142 ↗
63. Shi, Y., Shi, M., Wang, Y. & You, J. Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications. Signal Transduct. Target. Ther. 9, 322 (2024).10.1038/s41392-024-02002-z ↗
64. Hewitt, S. L. et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs. Sci. Transl. Med. 11, eaat9143 (2019).10.1126/scitranslmed.aat9143 ↗
65. Hamouda, A. E. I. et al. Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity. Nat. Commun. 15, 10635 (2024).10.1038/s41467-024-54877-9 ↗
66. Li, Z. et al. Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity. Front. Immunol. 15, 1455019 (2024).10.3389/fimmu.2024.1455019 ↗
67. Gote, V. et al. A comprehensive review of mRNA vaccines. Int. J. Mol. Sci. 24, 2700 (2023).10.3390/ijms24032700 ↗
68. Yeh, T.-F., Lin, C. & Sung, H.-C. A review of technological developments in lipid nanoparticle application for mRNA vaccination. Hum. Vaccines Immunother. 19, 2256040 (2023).10.1080/21645515.2023.2256040 ↗
69. Lu, Y. et al. Advancing mRNA vaccines: a comprehensive review of design, delivery, and efficacy in infectious diseases. Int. J. Biol. Macromol. 319, 145501 (2025).10.1016/j.ijbiomac.2025.145501 ↗
70. Kim, Y.-A. et al. Computational design of mRNA vaccines. Vaccine 42, 1831–1840 (2024).10.1016/j.vaccine.2023.07.024 ↗
71. Dolgin, E. ‘Remarkable’ AI tool designs mRNA vaccines that are more potent and stable. Nature https://doi.org/10.1038/d41586-023-01487-y (2023).10.1038/d41586-023-01487-y ↗
72. Castillo-Hair, S. M. & Seelig, G. Machine learning for designing next-generation mRNA therapeutics. Acc. Chem. Res. 55, 24–34 (2022).10.1021/acs.accounts.1c00621 ↗
73. Castillo-Hair, S. et al. Optimizing 5′UTRs for mRNA-delivered gene editing using deep learning. Nat. Commun. 15, 5284 (2024).10.1038/s41467-024-49508-2 ↗
74. Kosuri, S. & Church, G. M. Large-scale de novo DNA synthesis: technologies and applications. Nat. Methods 11, 499–507 (2014).10.1038/nmeth.2918 ↗
75. Bang, D. & Church, G. M. Gene synthesis by circular assembly amplification. Nat. Methods 5, 37–39 (2008).10.1038/nmeth1136 ↗
76. Karikó, K., Muramatsu, H., Ludwig, J. & Weissman, D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 39, e142 (2011).10.1093/nar/gkr695 ↗
77. Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S. & DeRosa, F. The promise of mRNA vaccines: a biotech and industrial perspective. npj Vaccines 5, 11 (2020).10.1038/s41541-020-0159-8 ↗
78. Verbeke, R., Lentacker, I., De Smedt, S. C. & Dewitte, H. The dawn of mRNA vaccines: the COVID-19 case. J. Control. Release 333, 511–520 (2021).10.1016/j.jconrel.2021.03.043 ↗
79. Schoenmaker, L. et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int. J. Pharm. 601, 120586 (2021).10.1016/j.ijpharm.2021.120586 ↗
80. Verbeke, R., Lentacker, I., De Smedt, S. C. & Dewitte, H. Three decades of messenger RNA vaccine development. Nano Today 28, 100766 (2019).10.1016/j.nantod.2019.100766 ↗
81. Roces, C. B. et al. Manufacturing considerations for the development of lipid nanoparticles using microfluidics. Pharmaceutics 12, 1095 (2020).10.3390/pharmaceutics12111095 ↗
82. Cullis, P. R. & Hope, M. J. Lipid nanoparticle systems for enabling gene therapies. Mol. Ther. 25, 1467–1475 (2017).10.1016/j.ymthe.2017.03.013 ↗
83. Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W. & Mastrobattista, E. Addressing the cold reality of mRNA vaccine stability. J. Pharm. Sci. 110, 997–1001 (2021).10.1016/j.xphs.2020.12.006 ↗
84. Wouters, O. J. et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet 397, 1023–1034 (2021).10.1016/S0140-6736(21)00306-8 ↗
85. Kis, Z., Kontoravdi, C., Dey, A. K., Shattock, R. & Shah, N. Rapid development and deployment of high-volume vaccines for pandemic response. J. Adv. Manuf. Process. 2, e10060 (2020).10.1002/amp2.10060 ↗
86. vander Straeten, A. et al. A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines. Nat. Biotechnol. 42, 510–517 (2024). This article reports a standalone microneedle vaccine printer that enables decentralized manufacture of thermostable mRNA–LNP COVID-19 vaccines without cold-chain requirements.10.1038/s41587-023-01774-z ↗
87. Han, J. et al. On-patient medical record and mRNA therapeutics using intradermal microneedles. Nat. Mater. 24, 794–803 (2025). This article reports a quantum dot-encoded on-patient medical record platform using microneedles delivering mRNA–LNP vaccine, enabling reliable tracking of vaccine administration in low-resource settings.10.1038/s41563-024-02115-4 ↗
88. Skerritt, J. H., Tucek-Szabo, C., Sutton, B. & Nolan, T. The platform technology approach to mRNA product development and regulation. Vaccines 12, 528 (2024).10.3390/vaccines12050528 ↗
89. Knezevic, I., Liu, M. A., Peden, K., Zhou, T. & Kang, H.-N. Development of mRNA vaccines: scientific and regulatory issues. Vaccines 9, 81 (2021).10.3390/vaccines9020081 ↗
90. Skerritt, J. H. Considerations for mRNA product development, regulation and deployment across the lifecycle. Vaccines 13, 473 (2025).10.3390/vaccines13050473 ↗
91. Daniel, S., Kis, Z., Kontoravdi, C. & Shah, N. Quality by design for enabling RNA platform production processes. Trends Biotechnol. 40, 1213–1228 (2022).10.1016/j.tibtech.2022.03.012 ↗
92. Gunter, H. M. et al. mRNA vaccine quality analysis using RNA sequencing. Nat. Commun. 14, 5663 (2023).10.1038/s41467-023-41354-y ↗
93. Jones, C. H. et al. Breaking the mold with RNA—a “RNAissance” of life science. npj Genom. Med. 9, 2 (2024).10.1038/s41525-023-00387-4 ↗
94. Patel, P. et al. Regulatory agilities impacting review timelines for Pfizer/BioNTech’s BNT162b2 mRNA COVID-19 vaccine: a retrospective study. Front. Med. 10, 1275817 (2023).10.3389/fmed.2023.1275817 ↗
95. Bouderhem, R. Challenges faced by states and the WHO in efficiently regulating the use of mRNA vaccines. Med. Sci. Forum 26, 1 (2024).
96. Cavaleri, M. et al. A roadmap for fostering timely regulatory and ethics approvals of international clinical trials in support of global health research systems. Lancet Glob. Health 13, e769–e777 (2025).10.1016/S2214-109X(24)00515-1 ↗
97. Chisholm, O. & Critchley, H. Future directions in regulatory affairs. Front. Med. 9, 1082384 (2022).10.3389/fmed.2022.1082384 ↗
98. Slaoui, M. & Hepburn, M. Developing safe and effective covid vaccines — operation warp speed’s strategy and approach. N. Engl. J. Med. 383, 1701–1703 (2020).10.1056/NEJMp2027405 ↗
99. Rathore, A. S. & Winkle, H. Quality by design for biopharmaceuticals. Nat. Biotechnol. 27, 26–34 (2009).10.1038/nbt0109-26 ↗
100. Bouderhem, R. Access to COVID-19 vaccines: a new global approach. Vaccines 10, 1795 (2022).10.3390/vaccines10111795 ↗